Genelux (GNLX)

• Market cap: $305M
• 1 day: 1.51%
• 5 days: 1.51%
• 1 month: 92.38%
• 3 months: 138.35%
• 6 months: 200.37%
• Year to date: 235.27%
• 1 year: 150.93%
• 5 years: 31.38%
• 10 years: 31.38%
• Sector: Healthcare
• Industry: Biotechnology

About: Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Employees: 24